Victory Capital Management Inc. Buys 923 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Victory Capital Management Inc. raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,217 shares of the medical research company’s stock after purchasing an additional 923 shares during the period. Victory Capital Management Inc. owned 0.08% of Bio-Rad Laboratories worth $7,299,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIO. Venturi Wealth Management LLC raised its position in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories during the 3rd quarter valued at approximately $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories during the 4th quarter valued at approximately $33,000. UMB Bank n.a. raised its position in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new position in Bio-Rad Laboratories during the 4th quarter valued at approximately $38,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $255.34 on Friday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.99. The stock’s 50 day moving average is $311.97 and its 200 day moving average is $327.95. Bio-Rad Laboratories, Inc. has a twelve month low of $244.00 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIO has been the subject of a number of recent analyst reports. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.